Compare PRTH & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTH | IVVD |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | 1019 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.1M | 437.1M |
| IPO Year | N/A | 2021 |
| Metric | PRTH | IVVD |
|---|---|---|
| Price | $5.64 | $1.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $8.00 | ★ $8.75 |
| AVG Volume (30 Days) | 259.4K | ★ 1.9M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $10.60 | $143.48 |
| Revenue Next Year | $7.92 | $25.40 |
| P/E Ratio | $10.38 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $4.44 | $0.46 |
| 52 Week High | $8.89 | $3.07 |
| Indicator | PRTH | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 51.22 |
| Support Level | $5.22 | $1.41 |
| Resistance Level | $6.01 | $2.01 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 67.52 | 87.69 |
Priority Technology Holdings Inc is a provider of merchant acquiring and commercial payment solutions to small and medium business enterprises in the United States. The company has three reportable segments which are SMB Payments, B2B Payments, and Enterprise Payments. SMB Payments segment which generates the majority of revenue provides full-service acquiring and payment-enabled solutions for B2C transactions, leveraging Priority's proprietary software platform, distributed through ISO; the B2B Payments segment provides AP automation solutions to corporations, software partners, & industry FIs: and Enterprise Payments segment provides embedded payment & treasury solutions to enterprise customers to modernize legacy platforms & accelerate software partners' strategies to monetize payments.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.